Generic Name and Formulations:
Ofloxacin 0.3%; oph. soln; contains benzalkonium chloride.
Indications for OCUFLOX:
Susceptible infections of the conjuctiva and corneal ulcer.
Adults and Children:
<1yr: not established. ≥1yr: Conjunctivitis: 1–2 drops every 2–4hrs for 2 days, then 4 times daily for 5 more days. Corneal ulcer: 1–2 drops every 30mins while awake and at 4hrs & 6hrs after retiring for sleep for 2 days, then 1–2 drops every 1hr while awake for days 3 through 7–9, then 1–2 drops 4 times daily through treatment completion.
Discontinue if superinfection or hypersensitivity occurs. Pregnancy. Nursing mothers: not recommended.
Possible potentiation of theophylline, caffeine, oral anticoagulants, cyclosporine if systemic absorption occurs.
Ocular burning/discomfort, redness, itching, chemical conjunctivitis/keratitis, ocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, eye pain.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities